Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUMP IV trial of adjuvant hepatic arterial infusion pump chemotherapy after resection of intrahepatic cholangiocarcinoma
2024-513726-33-00Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of floxuridine in intrahepatic cholangiocarcinoma (ICC), sponsored by Erasmus MC. Primary endpoint: Two-year hepatic recurrence free survival. Planned start Oct 2024; status: authorised.
02
Drugs
floxuridine
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2024-513726-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513726-33-00.